Search

Additional file 1: Figure S1. Oscillatory rheology of aPD-L1-PexD-Gel in (a) dynamic time sweep, (b) dynamic strain sweep, and (c) dynamic frequency sweep. Figure S2. Use gel to stick the two kidneys of the mouse together. Figure S3. Invitro cytotoxicity after 24 h of different treatments of B16-F10 cells with different concentrations of DOX and PexD. Data are expressed as mean �� SD (n = 3). Figure S4. Representative western blot analysis of HMGB1 release from B16-F10 cells treated with PexD or DOX for 24 h at 37 ���. Figure S5. Representative flow cytometric analysis of CD80+ CD86+ cells. Data are expressed as mean �� SD (n = 3). Figure S6. Photos of Bouin���s solution stained whole lungs and H&E staining of the lung slices collected from Tumour, DOX, Platelet-DOX, PexD, Saline groups. Red arrows demonstrate the visible metastatic site. Scale bars: 1 mm. Figure S7. In vivo targeting ability of Pex. (A) In vivo biodistribution at different times after i.v. injection of DiR-labeled Pex or an equivalent dose of free DiR. (1 mg kg���1) (n = 3) (B) Fluorescent imaging of residual tumours and main organs at 3 h and 12 h post-injection, respectively. Data are expressed as mean �� SD (n = 3). (H: heart; Li: liver; S: spleen; Lu: lung; K: kidney; T: tumour) (C) Quantitative analysis of fluorescent intensities of residual tumours and major organs at 3 h and 12 h post-injection. Data are presented as mean �� SD (n = 3). ***p